Skip to main content
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. logo

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. — Investor Relations & Filings

Ticker · 2395 ISIN · JP3379950003 LEI · 529900C10QR47J2U5R44 T Professional, scientific and technical activities
Open in API
Filings indexed 68 across all filing types
Latest filing 2022-07-25 Major Shareholding Noti…
Country JP Japan
Listing T 2395

About SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

https://en.snbl.com/

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a contract research organization (CRO) providing comprehensive drug development services. Established in 1957 as Japan's first CRO, the company supports pharmaceutical clients throughout the development lifecycle, from preclinical safety studies to clinical trial management. SNBL offers a full suite of services, including safety assessments and clinical data management. A key area of innovation is its proprietary nasal drug delivery technology, SMART (Simple MucoAdhesive Release Technology). The company's mission is to contribute to medical advancement and alleviate patient suffering by supporting the creation of new pharmaceuticals.

Recent filings

Filing Released Lang Actions
訂正報告書（大量保有報告書・変更報告書）
Major Shareholding Notification Classification · 100% confidence The document is a 'Large Shareholding Report' (大量保有報告書) filed in accordance with the Financial Instruments and Exchange Act of Japan. It details the acquisition of shares by Shin Nippon Biomedical Laboratories, Ltd. in Inabata Research, specifically noting a change in shareholding percentage and the intent to make the issuer a wholly-owned subsidiary. This type of regulatory filing regarding significant ownership thresholds is classified as a Major Shareholding Notification.
2022-07-25 Japanese
変更報告書
Major Shareholding Notification Classification · 100% confidence The document is a 'Large Shareholding Report' (大量保有報告書) filed in Japan, which is a regulatory requirement when an entity acquires a significant stake in another company. The content details the acquisition of shares by Shin Nippon Biomedical Laboratories, Ltd. in Inari Research, specifically noting a change in shareholding percentage and the intent to make the target a wholly-owned subsidiary. This falls under the category of Major Shareholding Notification (MRQ).
2022-07-21 Japanese
大量保有報告書
Major Shareholding Notification Classification · 100% confidence The document is a 'Large Shareholding Report' (大量保有報告書) filed in Japan, which is a regulatory requirement when an entity acquires a significant percentage of a company's shares. This specific document details Shin Nippon Biomedical Laboratories, Ltd.'s acquisition of shares in Inabata Research, resulting in a 92.31% ownership stake. In the provided classification schema, notifications of changes in significant share ownership levels are categorized as 'Major Shareholding Notification' (MRQ).
2022-07-14 Japanese
公開買付報告書
M&A Activity Classification · 100% confidence The document is a '公開買付報告書' (Report on Results of Tender Offer) filed with the Kanto Local Finance Bureau. It details the results of a tender offer (公開買付け) by Shin Nippon Biomedical Laboratories for Ina Research. This document type is specifically related to M&A activity and takeover bids, falling under the 'TAR' (M&A Activity) category.
2022-07-14 Japanese
訂正公開買付届出書
M&A Activity Classification · 100% confidence The document is a 'Correction of the Tender Offer Registration Statement' (訂正公開買付届出書) filed by Shin Nippon Biomedical Laboratories, Ltd. regarding the acquisition of Ina Research Inc. It contains detailed information about the tender offer, including the purpose, background, and terms of the acquisition. This document is a formal regulatory filing required under the Financial Instruments and Exchange Act of Japan. It is not a report publication announcement (RPA) because it is the primary regulatory filing itself, nor is it a standard 10-K or IR report. It fits best under the 'Regulatory Filings' category as it is a specific legal disclosure document for a tender offer.
2022-06-29 Japanese
内部統制報告書－第49期(令和3年4月1日－令和4年3月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act (金融商品取引法) in Japan. This type of report details the company's internal control framework, evaluation scope, and results regarding financial reporting. It is a standalone regulatory requirement distinct from the full Annual Report (10-K) or a simple announcement. Given the provided categories, 'Audit Report / Information' (AR) is the most appropriate classification as it covers internal control assessments and regulatory compliance reporting.
2022-06-29 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.